XML 13 R2.htm IDEA: XBRL DOCUMENT v3.26.3
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Sep. 30, 2026
Dec. 31, 2025
Current assets:    
Cash and cash equivalents $ 11,417,000 $ 3,006,000
Prepaid expenses and other current assets 1,146,000 392,000
Total current assets 12,563,000 3,398,000
Property and equipment, net 58,000 162,000
Operating lease right-of-use asset 798,000 1,052,000
Other assets 710,000 948,000
Total assets 14,129,000 5,560,000
Current liabilities:    
Accounts payable 981,000 942,000
Accrued clinical trials expenses 929,000 1,426,000
Accrued compensation 981,000 2,872,000
Other accrued expenses 1,681,000 1,657,000
Total current liabilities 4,572,000 6,897,000
Convertible notes at fair value, including related party amount of $1,969 and $34,600 at September 30, 2026 and December 31, 2025, respectively 1,969,000 34,600,000
Operating lease liability 821,000 893,000
Derivative liability   14,879,000
Warrant liabilities 4,353,000 3,276,000
Contingent consideration liability 6,000 42,000
Other liabilities 22,000  
Total liabilities 11,743,000 60,587,000
Commitments and contingencies (Note 7)
Stockholders' equity (deficit):    
Class A common stock, $0.0001 par value; 1,040,000,000 shares authorized at September 30, 2026 and December 31, 2025, and 59,084,675 and 12,105,902 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively 14,000 9,000
Additional paid-in capital 483,674,000 415,783,000
Accumulated deficit (481,302,000) (470,819,000)
Total stockholders' equity (deficit) 2,386,000 (55,027,000)
Total liabilities and stockholders' equity (deficit) $ 14,129,000 $ 5,560,000